Skip to content

Released Aug 8, 2019, before the open

10-Q filed Aug 8, 2019, 39 days after period end · 0001144204-19-038552

Q2 2019 · 10-Q
Revenue$12.25M+510.5% vs Q2 2018+17.3% vs Q1 2019
Net Income-$7.74MN/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.52N/M vs Q2 2018N/M vs Q1 2019
Operating Income-$5,839,000N/M
Operating Cash Flowderived-$5,170,000N/M
Free Cash Flowderived-$5,207,000N/M
Margins · derived
Operating margin-47.7%+288.5 pt vs Q2 2018
Net margin-63.2%+358.6 pt vs Q2 2018

What the release said

The release

Same quarter

MetricQ2 2019Q2 2018Q2 2017Q2 2016
Revenue$12.25M$2.01M$6.36M$1.77M
Net Income-$7.74M-$8.46M$450.00K-$10.85M
EPS Diluted-$0.52-$0.06-$0.06-$0.11

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR